Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4

Conditions

Mastocytosis 4Recurrence 2Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mastocytosis, Systemic 2Gastrointestinal Stromal Tumors 2Blushing 2Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-intestinal Stromal Tumours 1Gastro-Intestinal Stromal Tumour 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

masitinib 4Imatinib Mesylate 3midostaurin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Stem Cell Transplantation 1Sodium Chloride 1Single-Cell Gene Expression Analysis 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Injections 1Hydroxychloroquine 1Dasatinib 1Cyclophosphamide 1Cromolyn Sodium 1Cladribine 1Busulfan 1BNT162 Vaccine 1AK002 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Mastocytosis × masitinib × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00831974 2018-12-11

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

AB Science

Phase 2 Completed
23 enrolled
Myeloid

Mastocytosis

NCT01266369 2018-12-10

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

AB Science

Phase 2 Completed
21 enrolled
Myeloid

Mastocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡